Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of bortezomib in advanced relapsed or refractory Waldenström macroglobulinemia
2006-004218-42Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib and dexamethasone in Waldenström macroglobulinemia (WM) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Response at 2 months, Response at 4 months and 1 more. Started Dec 2007; status: completed.
02
Drugs
bortezomibdexamethasone
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2006-004218-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004218-42.